Can I read Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe on EtoBox?

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe by M. de With; A. Sadlon; E. Cecchin; V. Haufroid; F. Thomas; M. Joerger; R.H.N. van Schaik; R.H.J. Mathijssen; C.R. Largiadèr is a Medicine article available to read on EtoBox.

What is Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe about?

## Background The main cause for fluoropyrimidine-related toxicity is deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European Medicines Agency (EMA) recommended two methods for pre-treatment DPD deficiency testing in clinical practice: phenotyping using endogenous uracil concentration or genotyping for __DPYD__ risk variant alleles. This study assessed the DPD testing implementation status in Europe before (2019) and after (2021) the release of the EMA recommendations. ## Methods The survey was conducted from 16 March 2022 to 31 July 2022. An electronic form with seven closed and three open questions was e-mailed to 251 professionals with DPD testing expertise of 34 European countries. A descriptive analysis was conducted. ## Results We received 79 responses (31%) from 23 countries. Following publication of the EMA recommendations, 87% and 75% of the countries reported an increase in the amount of genotype and phenotype testing, respectively. Implementation of novel local guidelines was reported by 21 responders (27%). Countries reporting reimbursement of both tests increased in 2021, and only four (18%) countries reported no coverage for

Who reads Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe?

Author

M. de With; A. Sadlon; E. Cecchin; V. Haufroid; F. Thomas; M. Joerger; R.H.N. van Schaik; R.H.J. Mathijssen; C.R. Largiadèr

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)